Takeda invests in new building for drug manufacturing

0
12


Vaccine production Dengue vaccine candidate: Takeda invests in new building for drug production

Editor: Alexander Stark

Exactly one year after the completion of the production facility in Singen, Takeda is investing another 74 million euros in the site. The company has now also started building a plant there to manufacture the active ingredient for its dengue vaccine candidate.

Company on the subject

The new building with an investment volume of 74 million euros is being built on the site of the Takeda production facility in Singen, Baden-W├╝rttemberg. (Bild: Takeda)

Singen – Takeda has now invested over 200 million euros in vaccine production at the Singen site. With the construction of a plant for the production of the active ingredient for his dengue vaccine candidate, everything from the production of the active ingredient and the vaccine to filling and final packaging to worldwide shipping should take place in one location. Up to 100 of the currently around 1000 employees in Singen will work in the new production building in the future.

The construction work started on schedule in September 2020. The symbolic groundbreaking ceremony did not take place until November 2nd due to the effects of the corona pandemic.

As soon as an effective Covid-19 vaccine is available in the required quantities and is to be delivered to the vaccination centers, a special logistical task also has to be dealt with.

In a virtual media discussion on November 26th, Dr. Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda, Dr. Dirk Oebels, Site Manager Singen, Gary Dubin, MD, Head Global Medical Office, Global Vaccine Business Unit at Takeda and Alan Kelly, Project Manager Vaccine Factory in Singen on the current status of this project, which is very important for Takeda worldwide and for the region. “The manufacture of a dengue vaccine has high priority within our global production network,” said Thomas Wozniewski.

Dengue is the fastest spreading mosquito-borne viral disease. An estimated 390 million people worldwide become infected with the pathogen every year – 500,000 of them have to be treated in hospital.

The importance of vaccines also plays an important role in the German government’s recently adopted strategy on global health. By 2030, the agenda envisages promoting research into vaccines, the provision of vaccine platforms and the expansion of vaccination programs at home and around the world. The aim is to specifically combat tropical diseases that have so far been neglected and that are associated with poverty.

(ID:47018383)



Source link
https://www.process.vogel.de/dengue-impfstoffkandidat-takeda-investiert-in-neubau-zur-wirkstoff-herstellung-a-983847/

LEAVE A REPLY

Please enter your comment!
Please enter your name here